<DOC>
	<DOCNO>NCT01969890</DOCNO>
	<brief_summary>The purpose study demonstrate granulocyte colony-stimulating factor ( G-CSF ) therapy addition state-of-the-art treatment ( pharmacological non pharmacological ) safe significantly improve clinical outcome patient reduce left ventricular ejection fraction ( LVEF ) ( ≤45 % ) successful reperfusion large anterior acute myocardial infarction .</brief_summary>
	<brief_title>STem cElls Mobilization Acute Myocardial Infarction Outcome Trial</brief_title>
	<detailed_description>Post infarction heart failure ( HF ) remain major cause morbidity mortality . In United States , three million patient , 700.000 Italy , cardiac failure common cause ischemic heart disease . The major goal improve post infarction LV function would stimulation neovascularization enhancement regeneration cardiac myocytes within infarcted area . Recent experimental study suggest bone marrow-derived progenitor cell ( BMCs ) circulate endothelial progenitor cell ( cEPCs ) contribute regeneration infarcted myocardium , enhance neovascularization ischemic myocardium , prevent cardiomyocyte apoptosis , alter scar formation reduce development myocardial fibrosis , thereby , improve cardiac function . G-CSF hematopoietic cytokine produce monocyte , fibroblast endothelial cell . G-CSF known multiple function normal , steady-state hematopoiesis . It routinely use mobilize CD34+ hematopoietic stem cell BM peripheral blood , thus enable easy collection compare BM aspirate procedure . The proven efficacy safety G-CSF , healthy donor patient haematological disease , along favourable result study CD34+ cell transplantation patient MI ischemia , suggest G-CSF base BMC transplantation may efficacy patient MI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Patients affect acute anterior ST elevation myocardial infarction ( STEMI ) undergo primary percutaneous coronary intervention ( PCI ) PCIrescue persistent occlusion coronary artery , Time symptomtoballoon ( ≥3 h ≤12h ≤24 h symptom persist ) , Thrombolysis Myocardial Infarction ( TIMI ) flow post PCI ≥2 , Evidence leave ventricular ( LV ) dysfunction ( EF biplane ≤45 % ) ≤24 h revascularization , Men woman age ≥18 year ≤75 year , Informed consent must sign proceeding study procedure . Previous anterior MI , Recent MI ( within 1 month ) , Known previous LV dysfunction ( EF &lt; 45 % ) , Patients angiographic evidence coronary anatomy suitable PCI , need coronary artery bypass grafting ( CABG ) , Valve disease require surgical correction , History previous cardiac surgery PCI LAD within 6 month , Previous current document history leukemia , myeloproliferative myelodysplastic disorder , Previous current document history malignant disease , Haemoglobin &lt; 10 mg/dl , White blood cell ( WBC ) &gt; 25.000 mm3 , Platelet &lt; 50.000 mm3 , Sepsis , Known HIV infection , Immune system disease , Interstitial lung disease Serious concomitant medical condition ( ischemic heart disease ) , Pregnancy breast feeding , Documented alcohol drug abuse , Anticipated poor compliance . Current participation clinical trial investigational product Other cell therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>